Alzheimer disease (AD) is the most common form of dementia. Pathologically, AD is
characterized by amyloid plaques and neurofibrillary tangles in the brain, with associated …

Blood–brain barrier pathology is recognised as a central factor in the development of many
neurological disorders, but much less is known about the role of the blood–brain barrier in …

Tau has become an attractive alternative target for passive immunotherapy efforts for
Alzheimer's disease (AD). The anatomical distribution and extent of tau pathology correlate …

Amyloid plaques, consisting of deposited beta-amyloid (Aβ), are a neuropathological
hallmark of Alzheimer's Disease (AD). Cerebral vessels play a major role in AD, as Aβ is …

The kinetics of amyloid beta turnover within human brain is still poorly understood. We
previously found a dramatic decline in the turnover of Aβ peptides in normal aging. It was not …

Misfolded proteins in Alzheimer's disease and Parkinson's disease follow a well-defined
connectomics-based spatial progression. Several anti-tau and anti-alpha synuclein (aSyn) …

Background ALZ-801 is an orally available, valine-conjugated prodrug of tramiprosate.
Tramiprosate, the active agent, is a small-molecule β-amyloid (Aβ) anti-oligomer and …

Objective To examine the differential diagnostic significance of cerebrospinal fluid (CSF)
biomarkers reflecting Alzheimer's disease-related amyloid β (Aβ) production and …

Here, we present the first case-study where microdialysis is used to investigate the
pharmacokinetics of antibody in different regions of rat brain. Endogenous IgG was used to …

Background Amyloid beta (Aβ) oligomers play a critical role in the pathogenesis of
Alzheimer's disease (AD) and represent a promising target for drug development …